These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28126367)

  • 21. The effect of 17α-hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage.
    Rafael TJ; Mackeen AD; Berghella V
    Am J Perinatol; 2011 May; 28(5):389-94. PubMed ID: 21380984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
    Awwad J; Usta IM; Ghazeeri G; Yacoub N; Succar J; Hayek S; Saasouh W; Nassar AH
    BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birth.
    Byrns MC
    J Steroid Biochem Mol Biol; 2014 Jan; 139():173-81. PubMed ID: 23410596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
    Sibai BM; Istwan NB; Palmer B; Stanziano GJ
    Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gestiva for preventing prematurity: a new view of an old therapy.
    Cypher R
    Nurs Womens Health; 2007 Jun; 11(3):322-5. PubMed ID: 17883780
    [No Abstract]   [Full Text] [Related]  

  • 26. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of hydroxyprogesterone caproate to prevent preterm labour in uterine didelphys: a case report.
    Ng KS; Ng BK; Lim PS; Shafiee MN; Abdul Karim AK; Omar MH
    Horm Mol Biol Clin Investig; 2016 Sep; 27(3):89-91. PubMed ID: 26684353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reply: To PMID 23433324.
    Senat MV; Rozenberg P
    Am J Obstet Gynecol; 2013 Sep; 209(3):283-4. PubMed ID: 23628261
    [No Abstract]   [Full Text] [Related]  

  • 29. Progesterone.
    Maggio L; Rouse DJ
    Clin Obstet Gynecol; 2014 Sep; 57(3):547-56. PubMed ID: 24936913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth.
    Heyborne KD; Allshouse AA
    Am J Perinatol; 2016 Oct; 33(12):1191-7. PubMed ID: 27464018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
    Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
    Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 17-alpha-hydroprogesterone caproate and cervical changes.
    Facchinetti F
    Am J Obstet Gynecol; 2010 Sep; 203(3):e9; author reply e10. PubMed ID: 20537309
    [No Abstract]   [Full Text] [Related]  

  • 33. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial.
    Combs CA; Garite T; Maurel K; Das A; Porto M;
    Am J Obstet Gynecol; 2011 Mar; 204(3):221.e1-8. PubMed ID: 21376161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study.
    O'Brien JM; Ho SJ; Istwan NB; Stanziano GJ; Rhea DJ; Barton JR
    Am J Perinatol; 2010 Feb; 27(2):157-62. PubMed ID: 19644788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length.
    Romero J; Rebarber A; Saltzman DH; Schwartz R; Peress D; Fox NS
    Am J Obstet Gynecol; 2012 Jul; 207(1):51.e1-5. PubMed ID: 22595378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality related to 17-OHPC exposure is an important safety outcome.
    O'Brien JM
    Am J Obstet Gynecol; 2013 Sep; 209(3):282-3. PubMed ID: 23628265
    [No Abstract]   [Full Text] [Related]  

  • 37. Is 17α-hydroxyprogesterone caproate contraindicated in twin gestations?
    Romero R; Conde-Agudelo A
    BJOG; 2015 Jan; 122(1):6-7. PubMed ID: 25280114
    [No Abstract]   [Full Text] [Related]  

  • 38. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial.
    Senat MV; Porcher R; Winer N; Vayssière C; Deruelle P; Capelle M; Bretelle F; Perrotin F; Laurent Y; Connan L; Langer B; Mantel A; Azimi S; Rozenberg P;
    Am J Obstet Gynecol; 2013 Mar; 208(3):194.e1-8. PubMed ID: 23433324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of progestogens for the prevention of premature birth.
    Schindler AE
    J Steroid Biochem Mol Biol; 2005 Dec; 97(5):435-8. PubMed ID: 16198556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. There is still insufficient data to recommend screening twin pregnancies with transvaginal ultrasound cervical length, but this might change soon!
    Gimovsky A; Berghella V
    BJOG; 2015 Jan; 122(1):38. PubMed ID: 25145404
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.